Recent ATAI News
- atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference • GlobeNewswire Inc. • 06/26/2024 11:00:17 AM
- atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a • GlobeNewswire Inc. • 06/20/2024 11:00:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 12:00:49 PM
- atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference • GlobeNewswire Inc. • 05/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 11:10:17 AM
- atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors • GlobeNewswire Inc. • 05/23/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:30:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:53:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:15:45 AM
- atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates • GlobeNewswire Inc. • 05/15/2024 10:59:58 AM
- atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression • GlobeNewswire Inc. • 04/24/2024 11:00:38 AM
- atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology • GlobeNewswire Inc. • 04/17/2024 11:00:01 AM
- atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights • GlobeNewswire Inc. • 03/28/2024 11:00:14 AM
- atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression • GlobeNewswire Inc. • 03/27/2024 11:00:33 AM
- atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 • GlobeNewswire Inc. • 03/04/2024 01:00:18 PM
- atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 10:00:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:29:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 10:05:28 PM
- atai Life Sciences Appoints Anne Johnson as Chief Financial Officer • GlobeNewswire Inc. • 02/06/2024 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 12:46:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:28:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:53:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:20:38 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM